JP2016104790A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104790A5
JP2016104790A5 JP2016006778A JP2016006778A JP2016104790A5 JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5 JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5
Authority
JP
Japan
Prior art keywords
protein
vector
tissue
dna encoding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016006778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016104790A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104790A publication Critical patent/JP2016104790A/ja
Publication of JP2016104790A5 publication Critical patent/JP2016104790A5/ja
Ceased legal-status Critical Current

Links

JP2016006778A 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬 Ceased JP2016104790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008119324 2008-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014019961A Division JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Publications (2)

Publication Number Publication Date
JP2016104790A JP2016104790A (ja) 2016-06-09
JP2016104790A5 true JP2016104790A5 (enExample) 2016-07-21

Family

ID=41255155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬
JP2016006778A Ceased JP2016104790A (ja) 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Country Status (10)

Country Link
US (1) US20110097309A1 (enExample)
EP (1) EP2301560A4 (enExample)
JP (3) JP5814549B2 (enExample)
KR (1) KR20110027665A (enExample)
CN (1) CN102076351A (enExample)
AU (1) AU2009240885A1 (enExample)
BR (1) BRPI0911436A2 (enExample)
CA (1) CA2722906A1 (enExample)
RU (1) RU2010148785A (enExample)
WO (1) WO2009133940A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722906A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
BR112012009973A2 (pt) 2009-10-28 2017-07-25 Genomix Co Ltd promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
US10364276B2 (en) 2011-04-26 2019-07-30 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
TR201807769T4 (tr) 2012-10-25 2018-06-21 Genomix Co Ltd HMGB1 fragmanı kullanılarak spinal kord yaralanmasının tedavi edilmesine yönelik yeni yöntem.
RU2647467C2 (ru) 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
US10894082B2 (en) * 2015-09-14 2021-01-19 UNIVERSITé LAVAL Anti-S100A8 for treating leukemia
CA3051825A1 (en) 2017-01-27 2018-08-02 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3617222A4 (en) 2017-04-25 2021-01-20 Shionogi & Co., Ltd PEPTIDE ALLOWING TO INDUCE THE REGENERATION OF A TISSUE AND ASSOCIATED USE
EP3656850A4 (en) * 2017-07-18 2021-03-31 Shiseido Co., Ltd. MESENCHYMATIC STEM CELL INDUCTION AGENT
JPWO2019107566A1 (ja) 2017-12-01 2020-12-03 株式会社ステムリム 外胚葉性間葉系幹細胞およびその製造方法
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) * 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院（同济大学附属东方医院） 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666A (zh) * 2025-09-22 2025-10-28 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
HK1047770A1 (zh) * 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
AU2002304710A1 (en) * 2001-04-30 2002-11-11 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
CN1518604A (zh) * 2001-05-09 2004-08-04 克利夫兰大学医院 用新型基因标记、与之相关的方法和组合物来评测皮肤的紫外辐射损伤
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CN100484569C (zh) * 2001-11-19 2009-05-06 协和发酵工业株式会社 将多潜能干细胞从组织中流通到外周血的药物
CA2491321A1 (en) * 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
US7553488B2 (en) * 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
CA2512512A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
CA2520515C (en) * 2003-03-28 2012-08-28 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
WO2006008779A1 (en) * 2004-07-20 2006-01-26 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata Use of hmgb1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
EP2055308B1 (en) * 2006-10-30 2017-05-10 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
CA2722906A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
WO2009133943A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法

Similar Documents

Publication Publication Date Title
JP2016104790A5 (enExample)
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
JP2016514956A5 (enExample)
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR112016029318A2 (pt) tratamento de mielomas
WO2015197598A3 (en) Multispecific antigen binding proteins
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
WO2016207273A3 (en) Multispecific antigen binding proteins
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
JP2017532302A5 (enExample)
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
CY1125513T1 (el) Προερχομενα απο λιπωδη ιστο στρωματικα αρχεγονα κυτταρα για χρηση σε αγωγη δυσαγωγων περιπλοκων περιπρωκτικων συριγγιων σε νοσο toy crohn
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA202091567A1 (ru) Химерные белки мти
JP2016516394A5 (enExample)
RU2021113516A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА